ASCO22: Pasi Janne, MD, PhD on lung cancer research
Lung cancer research at #ASCO22 . Non-small cell lung cancers with KRAS mutation respond to experimental drug adagrasib which also shows activity in brain metastasis. Dana-Farber's Pasi Janne, MD, PhD, is senior author and explains more.
This is a Phase two clinical trial of a drug called acid, which is a keras G 12 C specific inhibitor for patients with advanced non small cell lung cancer who have previously received chemotherapy and immune therapy. This is a population of patients where we have not had the successes of the targeted therapies to date, like we have with other subsets of lung cancer, like e g F R mutant or alka rearrange non small cell lung cancer. So this study Evaluated 112 patients who had previously been treated with chemotherapy and immunotherapy. They had an overall response rate of about 43 Uh and a median progression free survival of 6.5 months and an overall survival of 12.6 months. And interestingly, there was a subset of individuals there who had previously treated stable central nervous system metastases. And in those patients, about a third of them also had a response in the brain and particularly excited about the activity also in the central nervous system. Because brain metastases is a big problem for patients with lung cancer and uh being able to treat them with pharmacologic agents as opposed to surgery and or radiation certainly provides a new option for individuals in a new way to treat them
